(Q42268705)

19 October 2017

title

Is the GAIN Act a turning point in new antibiotic discovery? (English)

1 reference

19 October 2017

0 references

Eric D Brown

1

1 reference

19 October 2017

publication date

6 February 2013

1 reference

Canadian Journal of Microbiology

19 October 2017

published in

1 reference

19 October 2017

volume

59

1 reference

19 October 2017

issue

3

1 reference

19 October 2017

page(s)

153-156

1 reference

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

New targets and screening approaches in antimicrobial drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

The genetic landscape of a cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Multitarget ligands in antibacterial research: progress and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

New screens and targets in antibacterial drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

The chemical genomic portrait of yeast: uncovering a phenotype for all genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Diarylquinolines target subunit c of mycobacterial ATP synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Discovery research: the scientific challenge of finding new antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Drug discovery beyond the 'rule-of-five'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1139%2FCJM-2013-0089

21 January 2018

Identifiers

DOI

10.1139/CJM-2013-0089

1 reference

19 October 2017

1 reference